Haemonetics (HAE) Revenue (2009 - 2026)

Haemonetics has reported Revenue for 18 years, with the latest figure at $346.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 4.76% year-over-year to $346.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 1.97% YoY), and the FY2026 full-year result was $1.3 billion, down 1.97% from the prior year.
• Revenue for Q1 2026 stood at $346.4 million, up from $339.0 million in the prior quarter.
• The five-year high for Revenue was $348.5 million in Q4 2024, with the low at $259.8 million in Q1 2022.
• Average Revenue over 5 years is $316.5 million, with a median of $324.4 million recorded in 2025.
• Year-over-year, Revenue advanced 24.01% in 2022 and declined 5.27% in 2025.
• Tracing HAE's Revenue over 5 years: stood at $305.3 million in 2022, then grew by 10.14% to $336.2 million in 2023, then gained by 3.66% to $348.5 million in 2024, then retreated by 2.75% to $339.0 million in 2025, then increased by 2.18% to $346.4 million in 2026.
• The last three Revenue figures came in at $346.4 million (Q1 2026), $339.0 million (Q4 2025), and $327.3 million (Q3 2025), per Business Quant data.

Peer Comparison